Loading stock data…
Biogen Inc. (BIIB)
$202.19+1.57 (+0.78%)
Market ClosedLast close Jul 24
Biogen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biogen Inc. in the Healthcare sector is trading at $202.19 with a market capitalization of $28.9B. Wall Street consensus targets $227.59 (30 analysts), implying a +12.6% move over the next 12 months. The stock is currently near its 52-week high of $219.72, remaining 11.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.48B↑ | $2.28B↓ | $2.53B↓ | $2.65B↑ | $2.43B |
| Gross Profit | $1.82B↑ | $1.78B↓ | $1.86B↓ | $2.04B↑ | $1.80B |
| Operating Income | $459.80M↑ | $385.50M↓ | $606.50M↓ | $851.80M↑ | $625.20M |
| Net Income | $319.50M↑ | -$48.90M↓ | $466.50M↓ | $634.80M↑ | $240.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.05
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.36%
Volume
Today's trading volume
565,571
Recent News
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Profitable Stocks We Steer Clear Of
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first